Primary Cell (PMC) Dashboard

Cell / Cell culture products
Adipose tissue related
Bone / cartilage / tooth related
Pancreas related
Liver function related
Cardiovascular related
Mesenchymal stem cells (stromal cells)
Feeder cells
Tumor cell line
Nerve / macrophage related
Coating reagents
Tissue-derived cDNA

Assay Kits
Measurement kits
Dyeing kits
Detection / Purification Kits
Nervous / dementia related
Macrophage / immunity related
Artificial Bone
Peptides / Amino Acids
Antibodies

Exosome
Exosomes

Anti-glycation / Aging related
Fluorescent AGEs assays
Specific AGEs assays

α-Synuclein antibodies

Mainly for Parkinson's disease (PD), dementia with Lewy bodies (DLB), multiple system atrophy (MSA) research

α-synuclein antibodies are useful for research in Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA) research. It has been reported to show particularly high performance in immunohistochemical staining (IHC).

Background

What is α-Synuclein?

α-Synuclein is a 140-amino acid protein that is mainly expressed at presynaptic terminals. It is known to be observed as aggregates in glia-derived inclusions.

Although this protein does not have a folded structure in its native state, it undergoes structural changes, including fibrosis, as the disease progresses, and is believed to play a central role in pathogenesis. The N-terminal region of α-synuclein has a structure in which an 11-residue amino acid sequence with a consensus sequence (KTKEGV) is incompletely repeated seven times. 95) partially overlaps with Also, the C-terminus (aa96-140) is negatively charged.

These antibodies have been reported to perform well, especially in IHC.

Neurodegenerative disease marker antibodies

Novel antibodies that detect abnormal lesions in dementia and intractable neurological diseases
- target diseases include Alzheimer's disease, Parkinson's disease, ALS, tauopathy, etc. -

"Neurodegenerative diseases" such as Alzheimer's disease and Parkinson's disease are rapidly increasing in the current aging society, and have become a serious social problem. In recent years, new causative genes have been discovered one after another for amyotrophic lateral sclerosis (ALS), an intractable neurological disease, and the need for research to elucidate its pathology is increasing. Aggregation and accumulation of specific proteins in a series of these diseases have been suggested to cause neurotoxicity and cause lesions. Useful biomarkers are desired for construction of biomarkers, discovery of therapeutic agents, and development of therapeutic methods.
Cosmobio Antibody Collection "CAC: Cosmobio Antibody Collection" has so far entered antibodies for detecting abnormal phosphorylation of the causative protein TDP-43 of ALS. We have started sales of antibodies against "gene repeat sequence translation products" and new "4R-tau" specific antibodies recently published in papers.

Provided by: Dr. Shigeto Hasegawa, Department of Dementia and Higher Brain Function, Tokyo Metropolitan Institute of Medical Science

Neurodegenerative disease marker antibodies

References

1. M. Masuda, et al. , Inhibition of a-synuclein fibril assembly by small molecules: Analysis using epitope-specific antibodies. FEBS Letters . 583 , 787-791 . PMID 1918355 (2009)
. al. , Conversion of wild-type alpha-synuclein into mutant type fibrils and its propagation in the presence of A30P mutant. Journal of Biological Chemistry . 284 , 7940-7950 .